TABLE 2.

Model Results for Eculizumab and Efgartigimod Compared with Conventional Therapy

Deterministic analysis	Total costs $	QALYs	LYs	Incremental results
				Cost/QALY gained (same as cost per evLYG)	Cost/LY gaineda
Comparison of eculizumab to conventional therapy
Eculizumab plus CT	855,400	1.13	1.93	5,210,000	N/A
CT alone	95,500	0.98	1.93	–	–
Comparison of efgartigimod to conventional therapy
Efgartigimod plus CTb	692,700	1.27	1.93	2,076,000	N/A
CT alone	94,800	0.98	1.93	–	–

^a There were no differences in survival. Cost per life-year gained could not be calculated, whereas cost per evLYG is equal to the cost per QALY gained.

^b Efgartigimod was evaluated using a placeholder price.

evLYG = equal value of life-years gained; CT = conventional therapy; LY = life-year; N/A = not applicable; QALY = quality-adjusted life-year.